Since 2021-2022, the US Food and Drug Administration (FDA) has issued marketing bans to e-cigarette companies for various reasons, preventing them from selling their products. As a result, many e-cigarette companies have appealed to federal courts.
On August 26th, 2021.
The United States Food and Drug Administration (FDA) announced today that it has rejected 55,000 pre-market tobacco applications (PMTA) from three small electronic liquid manufacturers. The federal regulatory agency appears to indicate that it may not authorize bottled e-liquids with flavors other than tobacco. With just two weeks left before the September 9, 2021 grace period, this could mean that almost all of the remaining PMTAs will also be rejected.
The US Food and Drug Administration has stated that it will not authorize PMTA for flavored e-liquids.
September 2, 2021.
The agency is continuing to remove products sold by small electronic cigarette manufacturers without requiring them to first submit a PMTA. Products that were not submitted for review by September 9, 2020, should have been immediately removed from the market. The difficult and expensive PMTA process has hindered many small manufacturers, and many have continued to sell their products after the deadline.
The original article discusses how the US Food and Drug Administration (FDA) is continuing to send warning letters to the "PMTA Dodgers" regarding their compliance with tobacco regulations.
September 3, 2021.
The US Food and Drug Administration (FDA) has refused to conduct pre-market tobacco product application (PMTA) reviews for 300,000 varieties of flavoured electronic liquids. FDA has already refused PMTA for 55,000 applications from three small e-liquid manufacturers. As of 9 September, 6.5 million PMTAs had been submitted, and this decision eliminates 2% of the remaining two million applications.
The US Food and Drug Administration has rejected PMTA applications for 300,000 flavoring e-liquids.
September 9th, 2021
On September 9, 2021, the U.S. Food and Drug Administration (FDA) attempted to drum up excitement for the future of the e-cigarette industry at a meeting titled "Deciding the Future of E-cigarettes." However, the FDA did not issue product authorization and did not grant exemptions to manufacturers allowed to continue selling, nor did it provide enforcement discretion guarantees to companies whose products were not rejected. The meeting ultimately did not provide the industry with any concrete advancements.
Link to the original article: "PMTA Deadline: FDA leaves the e-cigarette industry twisting in the wind" The original article is using informal language and metaphors that may not be appropriate for a standard journalistic style. A more professional and objective rephrasing of the headline could be: "FDA's PMTA Deadline Forces E-cigarette Industry into Uncertainty
September 10, 2021.
The Tobacco Product Center of the FDA announced that since August, it has issued marketing denial orders (MDOs) to 168 manufacturers, rejecting nearly 1 million flavored products. When electronic cigarette products apply for PMTA for tobacco flavor products, those PMTAs will be rejected if "sufficient specific scientific evidence is not provided to demonstrate sufficient benefits to adult smokers to overcome the risks posed to young people.
On September 10th, the FDA has released 168 PMTA denials so far.
September 17, 2021
On September 10th, the FDA issued a Modified Risk Tobacco Product Order to 168 manufacturers of electronic cigarettes, encompassing nearly one million individual products. This follows an announcement on August 26th by the agency that products with flavors beyond tobacco and menthol must meet higher standards of evidence. Turner Point Brands, a publicly traded company, has confirmed that some of its pre-market tobacco applications have been rejected by the FDA for marketing.
The US Food and Drug Administration has issued MDOs (Modified Risk Tobacco Product Orders) to Turning Point Brands and other major e-cigarette companies, marking a turning point in the regulation of vaping products.
September 23, 2021.
Since September, 28 companies have received MDOs. All of the products that received marketing denial orders (MDOs) are flavored electronic cigarette products, and the total number of companies that have received PMTA MDOs before the launch of flavored products is now 323. The U.S. Food and Drug Administration says these companies have produced nearly 1.2 million flavored electronic cigarettes.
Original link: "Who has left? 323 e-cigarette companies have received MDOs." The article reports that 323 e-cigarette companies have received MDOs (Mandatory Decree Orders). It is unclear from the headline or article what the MDOs specifically entail or why they have been issued to these companies. Further information and clarification regarding the situation is needed.
September 23, 2021.
The publicly traded company Turning Point Brands has filed a petition with a federal court today, seeking a review of the FDA's regulation of its flavored electronic liquid MOD. This move represents a broad legal challenge by the e-cigarette industry against the FDA's ban on flavored products other than tobacco and menthol.
Original article link: "Turning Point Brands sues FDA, challenging denial of PMTA" Turning Point Brands has filed a lawsuit against the FDA, challenging the agency's denial of their PMTA (premarket tobacco product application).
October 4, 2021
Since October, at least two e-cigarette manufacturers that produce flavored electronic cigarette products have sued the FDA after receiving marketing denial orders (MDO). Turing Point Brands has also requested a federal court to suspend the execution of the FDA's MDO before appealing the ruling. Several other companies are expected to file their own lawsuits soon.
Original link: "More Vape Manufacturers Challenge PMTA Rejection" Translation: "A growing number of vape manufacturers are challenging the rejection of their PMTA applications.
On October 8th, 2021.
The United States Food and Drug Administration (FDA) has revoked marketing denial orders (MDOs) for certain electronic liquids. According to journalist Alex Norcia of Filter, the FDA has reinstated the TPB product for scientific review, and in response, the company withdrew its petition for review in federal court.
The US Food and Drug Administration Backtracks, Revoking MDO from Turning Point Brand.
October 14th, 2021
The US Food and Drug Administration (FDA) has responded to Triton Distribution's emergency motion to lift the agency's marketing denial order (MDO) on October 6th. This allows Triton to resume sales of its flavored electronic cigarette products while the court reviews Triton's request for reconsideration (though the FDA opposes this).
Original article link: "MDO Update: FDA and Triton in Court Documents Debate" The Food and Drug Administration (FDA) and Triton are currently engaged in a legal dispute, as revealed in court documents. The specifics of the argument have not been disclosed, but it is related to medical device regulation. This issue is still ongoing and the outcome is yet to be determined.
October 26th, 2021.
A federal court has granted Triton Distribution a stay, preventing the FDA from enforcing its marketing refusal order (MDO). A panel of three judges from the Fifth Circuit Court of Appeals ruled that Triton (also known as Wages and White Lion Investments, LLC) may succeed in their appeal against the MDO and that the FDA's order was too arbitrary. The decision allows Triton to continue selling its products, while the court reviews the FDA's refusal order.
The judges have rejected the FDA's "Surprise Switcheroo," leaving the issue for Triton to address.
November 15, 2021
For the first time since Vape company began questioning the FDA's marketing denial order (MDO), a federal court has denied a motion to stay the MDO pending completion of the review. The Michigan-based company submitted PMTAs for ten disposable e-cigarettes with e-liquid strength of 5%. They appealed the decision on October 4 to the Sixth Circuit Court of Appeals and filed a motion to stay pending appeal in October.
The court has rejected Breeze Smoke's motion for a pending review of their residency.
November 30th, 2021
On November 15th, Judge Paul Grimm of the regional court requested a retrial of the case brought by the plaintiffs, allowing them the opportunity to propose amendments to the judge's order. Their goal is for the judge to compel the FDA to clarify their progress regarding PMTA submissions from popular e-cigarette brands in the consumer market.
The anti-vaping organization is calling for Judge Grimm to monitor the progress of the PMTA by the FDA.
December 10, 2021
After the federal appeals court rejected Breeze Smoke's motion to suspend the FDA's marketing refusal order, the Michigan-based company has requested intervention from the US Supreme Court and issued a stay request. Breeze Smoke asked the Supreme Court to suspend the FDA MDO until it undergoes a full review by the Sixth Circuit Court of Appeals.
The Supreme Court has rejected the request for a stay by Weifeng Electronic Cigarette Company.
February 3, 2022
A federal court has temporarily halted the execution of the FDA's marketing denial order (MDO) issued to four electronic cigarette manufacturers, allowing them to undergo a comprehensive review in court while continuing their operations.
Link to original article: "Challenge to FDA is on the rise in court" The challenge to the FDA is increasing in court, according to a recent report. It appears that more cases are being brought before the courts that question the FDA's authority and decision-making processes. This could lead to greater scrutiny of the agency's actions and policies, and potentially even changes to the way it operates. It remains to be seen how these challenges will play out in the legal system, but they highlight the increasing importance of accountability and transparency in government agencies.
April 8, 2022
The U.S. Food and Drug Administration (FDA) has issued a Marketing Denial Order (MDO) to Fontem US today, which prohibits the company from purchasing pods and electronic cigarette devices, as well as various flavored supplement pods. This is the first MDO issued against a large tobacco company's pod product for their electronic cigarette brand, myblu, for failing to submit a Premarket Tobacco Product Application (PMTA) for its release to the market.
Original link: "Myblu is the first major brand of pod devices to be rejected by the FDA." In a significant development, the US Food and Drug Administration (FDA) has rejected Myblu, a major brand of pod devices. This is the first time a brand of pod devices has been denied approval by the FDA. Myblu's rejection raises questions about the safety and regulatory compliance of similar products in the market. This decision by the FDA reflects the agency's commitment to protecting public health and ensuring that only safe and effective products are available to consumers.
June 22, 2022.
The Food and Drug Administration (FDA) will reportedly reject Juul Labs' tobacco application for pre-market approval (PMTA) and issue a marketing denial order (MDO) for the company's devices and pods, according to the Wall Street Journal. The FDA also announced plans to implement a program that removes most nicotine from cigarettes. However, many observers believe this policy will require the agency to allow the sale of various attractive non-combustible products to prevent a massive black market for tobacco.
According to insider sources, the FDA will reject JUUL's PMTA application.
July 6, 2022
The US Food and Drug Administration has rejected a decision to pull all Juul products off the shelves and issued an administrative order last night, suspending previous orders. The FDA announced on Twitter that it had "identified some unique scientific issues in the JUUL application that warrant further review".
Original Text: "美国食品药品监督管理局混乱：该机构扭转局面，给予Juul住宿" Rewritten: "Chaos at the US Food and Drug Administration: Agency grants accommodation to Juul amidst turmoil
July 19, 2022
Tobacco company Triton has filed an appeal, alleging that the FDA acted unlawfully by changing requirements for successful pre-market tobacco applications (PMTAs) after the application deadline had passed. Despite including information about youth use and marketing plans in its application, Triton's PMTA was refused by the FDA. Additionally, Triton argued that the FDA lacks the legal authority to require manufacturers to prove that flavored e-cigarette products are more effective than tobacco flavoring.
Original: 原文链接：《第五巡回法院对Triton的裁决》 Translation: The Fifth Circuit Court's Ruling on Triton
July 31, 2022
Currently, around 40 e-cigarette manufacturers are challenging the FDA's marketing denial order (MDO) in court, while the US Food and Drug Administration (FDA) has stated that an internal appeal by My Vape Order may not be resolved until January 2025.
The US Food and Drug Administration has announced that an MDO appeal will not be resolved until 2025.
To learn more about the legal disputes between the FDA and e-cigarette companies, click on the "FDA and E-cigarette Company Legal Disputes Summary" topic, which is regularly updated by 2FIRSTS.
Statement:
This article is based on compiled third-party information and is intended solely for industry exchange and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity or accuracy of the content. The translation of this article is only intended for industry exchange and research purposes.
Due to limitations in translation abilities, the translated article may not fully reflect the original text. Therefore, the original text should be considered the authoritative version.
2FIRSTS aligns entirely with the Chinese government regarding statements and positions related to domestic issues, matters involving Hong Kong, Macau and Taiwan, as well as foreign affairs.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
